DiaMedica Therapeutics (DMAC)

• Market cap: $152M
• 1 day: 2.02%
• 5 days: 0.57%
• 1 month: -40.90%
• 3 months: -38.00%
• 6 months: -17.48%
• Year to date: -35.75%
• 1 year: 36.15%
• 5 years: 2.31%
• 10 years: 14.19%
• Sector: Healthcare
• Industry: Biotechnology

About: DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Employees: 28

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

4,300% more call options, than puts

Call options by funds: $264K | Put options by funds: $6K

220% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 5

140% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 5

57% more capital invested

Capital invested by funds: $23.3M [Q3] → $36.5M (+$13.2M) [Q4]

13% more funds holding

Funds holding: 40 [Q3] → 45 (+5) [Q4]

2.68% more ownership

Funds ownership: 13.05% [Q3] → 15.74% (+2.68%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $10 182% upside
• Avg. target: $10 182% upside
• High target: $10 182% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Matthew Caufield 24% 1-year accuracy 16 / 68 met price target

182% upside $10

Buy Maintained

19 Mar 2025